Johnson & Johnson (NYSE:JNJ) Shares Sold by Alpha Omega Wealth Management LLC

Alpha Omega Wealth Management LLC lessened its holdings in Johnson & Johnson (NYSE:JNJ) by 1.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 52,658 shares of the company’s stock after selling 868 shares during the quarter. Johnson & Johnson accounts for about 1.5% of Alpha Omega Wealth Management LLC’s holdings, making the stock its 12th biggest position. Alpha Omega Wealth Management LLC’s holdings in Johnson & Johnson were worth $8,330,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of JNJ. Norges Bank purchased a new position in Johnson & Johnson in the fourth quarter valued at about $4,071,642,000. Wellington Management Group LLP raised its holdings in Johnson & Johnson by 16.4% during the fourth quarter. Wellington Management Group LLP now owns 24,019,725 shares of the company’s stock worth $3,764,852,000 after purchasing an additional 3,391,657 shares during the last quarter. International Assets Investment Management LLC boosted its position in Johnson & Johnson by 7,875.8% during the fourth quarter. International Assets Investment Management LLC now owns 2,090,384 shares of the company’s stock worth $327,647,000 after purchasing an additional 2,064,175 shares in the last quarter. Janney Montgomery Scott LLC acquired a new stake in Johnson & Johnson in the fourth quarter valued at $193,050,000. Finally, Global Assets Advisory LLC acquired a new position in shares of Johnson & Johnson during the 1st quarter worth $170,372,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on JNJ shares. The Goldman Sachs Group initiated coverage on shares of Johnson & Johnson in a report on Thursday, May 30th. They set a “neutral” rating and a $160.00 target price for the company. Morgan Stanley cut their price objective on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 17th. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Thursday, June 20th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Sunday. Finally, Bank of America decreased their price objective on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. Eight research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $174.07.

Johnson & Johnson Trading Up 0.2 %

NYSE JNJ opened at $146.16 on Monday. The company has a market cap of $351.76 billion, a P/E ratio of 9.11, a P/E/G ratio of 2.43 and a beta of 0.53. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $175.97. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94. The company has a 50-day moving average of $148.14 and a 200-day moving average of $154.05.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.64 by $0.07. The firm had revenue of $21.38 billion during the quarter, compared to analyst estimates of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. Johnson & Johnson’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.68 earnings per share. As a group, equities analysts predict that Johnson & Johnson will post 10.62 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st were given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.39%. The ex-dividend date was Monday, May 20th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s payout ratio is 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.